Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shuren To Lawmakers: Sequestration Is “Killing Us”

This article was originally published in The Gray Sheet

Executive Summary

CDRH Director Jeffrey Shuren fears the center won’t be able to meet commitments to hire new employees for FY 2014 if the sequester continues, he told members of the House Energy & Commerce Health Subcommittee last week.

You may also be interested in...



News Briefs: Senate Introduces User Fee Bill; Lawsuit Ends Over Conflict Minerals

Senators try to shield FDA user fees from sequestration. Court rejects business groups’ challenge to conflict minerals reporting law. More news in brief

CDRH Sequestration Impact: Training, Standards And Reg Science

CDRH Director Jeffrey Shuren detailed last week how federal sequestration cuts to FDA are impacting specific device center programs, including training, standards development and regulatory science. Shuren also signaled imminent policy releases from the center, including a finalized post-market surveillance plan.

FDA Issues Work Plan For Independent Assessment Of Pre-market Review Process

The assessment, called for by industry during the device user fee reauthorization, will be conducted by an independent consulting firm. The goal is to identify efficiencies in the device review process.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032585

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel